keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28448655/change-in-diabetic-retinopathy-through-2-years-secondary-analysis-of-a-randomized-clinical-trial-comparing-aflibercept-bevacizumab-and-ranibizumab
#1
Susan B Bressler, Danni Liu, Adam R Glassman, Barbara A Blodi, Alessandro A Castellarin, Lee M Jampol, Paul L Kaufman, Michele Melia, Harinderjit Singh, John A Wells
Importance: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents. Objective: To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME. Design, Setting, and Participants: Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab...
April 27, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28445077/effect-of-epiretinal-membranes-on-antivascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#2
Han Joo Cho, Jae Min Kim, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required...
April 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28436640/intravitreal-aflibercept-for-patients-with-diabetic-macular-edema-refractory-to-bevacizumab-or-ranibizumab-analysis-of-response-to-aflibercept
#3
Yen-Yi Chen, Pei-Yao Chang, Jia-Kang Wang
PURPOSE: To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients with diabetic macular edema (DME) refractory to ranibizumab or bevacizumab. DESIGN: A retrospective chart review. METHODS: From September 2013 to March 2016, we identified patients with DME who developed resistance to bevacizumab or ranibizumab. Three monthly intravitreal aflibercept injections were administered in refractory cases...
April 10, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28435211/erratum-prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion-corrigendum
#4
(no author information available yet)
[This corrects the article on p. 403 in vol. 11, PMID: 28260852.].
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28430321/comments-to-visual-and-anatomic-outcomes-after-conversion-to-aflibercept-in-neovascular-age-related-macular-degeneration-12-month-results
#5
Dan Călugăru, Mihai Călugăru
No abstract text is available yet for this article.
April 20, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28427072/anti-vascular-endothelial-growth-factor-injections-the-new-standard-of-care-in-proliferative-diabetic-retinopathy
#6
Xintong Li, Marco A Zarbin, Neelakshi Bhagat
For decades, panretinal photocoagulation (PRP) has been the standard of care for the treatment of proliferative diabetic retinopathy (PDR). The relatively recent advent of anti-vascular endothelial growth factor (VEGF) formulations for intravitreal injection has provided a fresh perspective on PDR treatment, especially in eyes with concurrent diabetic macular edema (DME). The anti-VEGF agent ranibizumab has demonstrated a potentially protective effect on eyes with DME in terms of progression to PDR in the RIDE/RISE trials, as has aflibercept in the VIVID/VISTA trials...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427070/practical-lessons-from-protocol-t-for-the-management-of-diabetic-macular-edema
#7
Lekha Mukkamala, Neelakshi Bhagat, Marco Zarbin
PURPOSE: To review the results of Diabetic Retinopathy Clinical Research Network Protocol T, as applied to clinical practice. METHODS: Review of major publications reporting the results of Protocol T, a randomized single-masked (in year-1 only), multicenter clinical trial comparing aflibercept, bevacizumab, and ranibizumab as treatment option for center-involving diabetic macular edema (DME). The main outcome measures were change in visual acuity (VA), central subfield thickness (CST) on optical coherence tomography, cost effectiveness, burden of care, and safety...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427067/intravitreal-aflibercept-in-diabetic-macular-edema-long-term-outcomes
#8
Ugo Introini, Giuseppe Casalino
For decades, macular laser photocoagulation has been the standard of care in the treatment of diabetic macular edema (DME). With the relatively recent advent of anti-vascular endothelial growth factor (VEGF) agents, DME treatment has entered a new era. VEGF is a well-known pro-angiogenic and pro-permeability factor involved in the pathogenesis of DME. VEGF blockade has proven remarkably effective at reducing DME and improving visual acuity (VA) in eyes with center involved DME causing VA loss in several randomized controlled trials (RCTs)...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427057/long-term-anatomical-and-functional-outcomes-in-patients-with-ischemic-central-retinal-vein-occlusion-treated-with-anti-vascular-endothelial-growth-factor-agents
#9
Irini Chatziralli, George Theodossiadis, Efstratios Parikakis, Panagiotis G Mitropoulos, Panagiotis Theodossiadis
PURPOSE: To evaluate the anatomical and functional outcomes in patients with ischemic central retinal vein occlusion (CRVO) treated with intravitreal anti-vascular endothelial growth factor (VEGF) agents. METHODS: This retrospective study included 15 treatment-naive patients with ischemic CRVO and macular edema who were treated with intravitreal ranibizumab or aflibercept. The main outcomes were the evolution of retinal ischemia over time, as well as the change in best corrected visual acuity (BCVA) and in central subfield thickness (CST) at month 24...
April 21, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28421399/effect-of-intravitreal-aflibercept-eylea-%C3%A2-on-retrobulbar-hemodynamics-in-patients-with-neovascular-age-related-macular-degeneration
#10
Mustafa Gok, Hasan Burhanettin Kapti
PURPOSE: To investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients with neovascular age-related macular degeneration (nAMD). METHODS: Twenty eyes of 20 patients with nAMD scheduled for single intravitreal aflibercept (Eylea(®)) injection and 20 fellow eyes (uninjected) were enrolled in this prospective interventional study. The hemodynamic parameters of the ophthalmic artery (OA), central retinal artery (CRA) and posterior ciliary artery (PCA) comprising peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) were measured by using color Doppler ultrasonography (CDU) in both injected and uninjected fellow eyes at baseline and 1 week after the injection...
April 18, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28413405/intravitreal-aflibercept-in-recalcitrant-radiation-maculopathy-due-to-external-beam-radiotherapy-for-nasopharyngeal-cancer-a-first-case-report
#11
Eleni Loukianou, Georgia Loukianou
PURPOSE: To present the safety and efficacy of intravitreal aflibercept (Eylea) in a patient with radiation maculopathy secondary to external beam radiotherapy for nasopharyngeal cancer unresponsive to other therapeutic options. METHODS: A 73-year-old female presented with decreased visual acuity in both eyes 18 months after completing 47 external beam cycles of radiation for nasopharyngeal cancer. On presentation, her best corrected visual acuity was 6/60 in the right eye and counting fingers from 1 meter in the left eye...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28406859/visual-acuity-improvement-when-switching-from-ranibizumab-to-aflibercept-is-not-sustained
#12
Cecilia S Lee, Alisa J Kim, Douglas Baughman, Catherine Egan, Clare Bailey, Robert L Johnston, Salim Natha, Rehna Khan, Christopher Brand, Toks Akerele, Martin McKibbin, Louise Downey, Saher Al-Husainy, Aaron Y Lee, Adnan Tufail
PURPOSE: To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration. METHODS: A multicenter, national, electronic medical record database study was performed. Patients undergoing six continuous monthly ranibizumab injections and then switched to continuous aflibercept were matched to those on continuous ranibizumab therapy. Matching was performed in a 2:1 ratio and based on visual acuity 6 months before and at the time of the switch, and the number of previous ranibizumab injections...
April 11, 2017: Retina
https://www.readbyqxmd.com/read/28405787/outcomes-of-switching-treatment-to-aflibercept-in-patients-with-macular-oedema-secondary-to-central-retinal-vein-occlusion-refractory-to-ranibizumab
#13
Vasileios Konidaris, Zahra Al-Hubeshy, Konstantinos T Tsaousis, Konstantina Gorgoli, Somnath Banerjee, Theodoros Empeslidis
PURPOSE: To assess the treatment outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRVO). METHODS: A prospective interventional study was conducted in a tertiary retina service in Leicester Royal Infirmary, UK, where patients with CRVO and associated macular oedema were recruited. First-line treatment involved three monthly ranibizumab injections. Non-responders were defined as patients who despite a minimum of three consecutive injections had persistent intraretinal fluid one month after the last injection...
April 12, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28402983/comparison-of-pro-re-nata-versus-bimonthly-injection-of-intravitreal-aflibercept-for-typical-neovascular-age-related-macular-degeneration
#14
Ryusaburo Mori, Koji Tanaka, Miho Haruyama, Akiyuki Kawamura, Koichi Furuya, Mitsuko Yuzawa
PURPOSE: The aim of this study was to clarify the 1-year outcomes of pro re nata (PRN) and bimonthly intravitreal injections of aflibercept (IVA) for typical neovascular age-related macular degeneration (tAMD) after the initial 3 monthly IVA. METHODS: We conducted a prospective, interventional study. Fifty-eight treatment-naïve patients with tAMD were randomly assigned to the PRN (30 patients) or the bimonthly (28 patients) treatment group. Both groups initially received 3 monthly IVA...
April 13, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28393046/intravitreal-aflibercept-for-ruptured-retinal-arterial-macroaneurysm
#15
Zafer Oztas, Serhad Nalcaci, Cezmi Akkin
No abstract text is available yet for this article.
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28393034/intravitreal-aflibercept-in-neovascular-age-related-macular-degeneration-previously-treated-with-ranibizumab
#16
Rachel Hui Fen Lim, Bhaskar Gupta, Peter Simcock
AIM: To report the change in visual acuity and central macular thickness (CMT) following treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration (nAMD) with suboptimum response to ranibizumab. METHODS: This was a retrospective study. The inclusion criteria were patients with nAMD who responded poorly to ranibizumab. Patients then received either 3 consecutive aflibercept injections followed by pro re nata (PRN) treatment or PRN alone...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28386497/bilateral-severe-sterile-inflammation-with-hypopyon-after-simultaneous-intravitreal-triamcinolone-acetonide-and-aflibercept-injection-in-a-patient-with-bilateral-marked-rubeosis-associated-with-ocular-ischemic-syndrome
#17
Ceren Durmaz Engin, Ziya Ayhan, Süleyman Men, Aylin Yaman, A Osman Saatci
We report the clinical course of a diabetic patient with bilateral cataract and rubeosis in association with ocular ischemic syndrome and initially treated him with simultaneous intravitreal 2 mg aflibercept and 2 mg triamcinolone acetonide injection at the same setting prior to planned cataract surgery and further photocoagulation. However, sterile anterior segment inflammation characterized by hypopyon occurred four days apart in OU. Right eye developed the sterile inflammation at the third postinjection day and the left eye developed the sterile inflammation at the seventh postinjection day (two days after the uneventful cataract surgery with intraocular lens implantation) without any pain or significant redness...
2017: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/28384009/incidence-and-timing-of-the-first-recurrence-in-neovascular-age-related-macular-degeneration-comparison-between-ranibizumab-and-aflibercept
#18
Jae Hui Kim, Young Suk Chang, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To compare the incidence and timing of first recurrence between patients who were treated with ranibizumab and aflibercept in neovascular age-related macular degeneration (AMD). METHODS: This retrospective study included 120 patients who received the diagnosis of treatment-naive typical neovascular AMD or polypoidal choroidal vasculopathy (PCV) and were treated using either ranibizumab (n = 73) or aflibercept (n = 47). Recurrence within 10 months of the third injection was compared between the 2 treatment groups...
April 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28379655/recommended-guidelines-for-use-of-intravitreal-aflibercept-with-a-treat-and-extend-regimen-for-the-management-of-neovascular-age-related-macular-degeneration-in-the-asia-pacific-region-report-from-a-consensus-panel
#19
Adrian Koh, Paolo Lanzetta, Won Ki Lee, Chi-Chun Lai, Wai-Man Chan, Chung-May Yang, Chui Ming Gemmy Cheung
PURPOSE: To summarize recommendations for the use of intravitreal aflibercept with a treat-and-extend regimen to manage neovascular age-related macular degeneration (nAMD) in the Asia-Pacific region. Although anti-vascular endothelial growth factor therapies have improved the quality of life of patients with nAMD, a leading cause of blindness and visual impairment, the high treatment frequency recommended by current guidelines places a significant burden on patients and healthcare providers...
March 29, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28376554/-retinal-vein-occlusion-which-treatment-when
#20
A Bajor, A Pielen, L Danzmann
According to the latest findings, macular oedema due to retinal vein occlusion is best treated safely and effectively with near-term intravitreal anti-VEGF therapy (aflibercept, bevacizumab [off label], ranibizumab). After an initial upload of 3 monthly injections of anti-VEGF, the decision on re-injection should be based on OCT (rather than on visual acuity). After initial monthly injections, the "pro-re-nata" (PRN) and the "treat-and-extend" regimens have been predominantly used in the further course of therapy...
April 4, 2017: Klinische Monatsblätter Für Augenheilkunde
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"